BIOVITEX

Hazard statements (CLP)

H315, H319, H335

Code

Statements

H315

Causes skin irritation

SECTION 2: Hazards identification

Hazard labelling pursuant to EC Regulation 1272/2008 (CLP) and subsequent amendments and supplements. Classification of the substance or mixture

Signal word

Warning

Hazard statements

H319 Causes serious eye irritation. H315 Causes skin irritation. H335 May cause respiratory irritation.

Precautionary statements

P261 Avoid breathing dust / fume / gas / mist / vapours / spray. P280 Wear protective gloves / eye protection / face protection. P312 In case of malaise, contact an anti -anti / a doctor center P403+P233 Store in a well-ventilated place. Keep container tightly closed. P264 Wash your hands thoroughly after use.

Contains

L-CYSTEINE HCL

2.3 Other hazards

On the basis of available data, the product does not contain any PBT or vPvB in percentage ≥ than 0,1%. The product does not contain substances with endocrine disrupting properties in concentration ≥ 0.1%.

2.1 Classification of the substance or mixture

The product is classified as hazardous pursuant to the provisions set forth in (EC) Regulation 1272/2008 (CLP) (and subsequent amendments and supplements). The product thus requires a safety datasheet that complies with the provisions of (EU) Regulation 2020/878. Any additional information concerning the risks for health and/or the environment are given in sections 11 and 12 of this sheet. Hazard classification and indication: Eye irritation, category 2 H319 Causes serious eye irritation. Skin irritation, category 2 H315 Causes skin irritation. Specific target organ toxicity - single exposure, H335 May cause respiratory irritation.